229 related articles for article (PubMed ID: 15904473)
21. A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients.
Avşar E; Tiftikçi A; Poturoğlu S; Erzin Y; Kocakaya O; Dinçer D; Yıldırım B; Güliter S; Türkay C; Yılmaz U; Onuk MD; Bölükbaş C; Ellidokuz E; Bektaş A; Taşan G; Aytuğ N; Ateş Y; Kaymakoğlu S
Turk J Gastroenterol; 2013; 24(4):316-21. PubMed ID: 24254262
[TBL] [Abstract][Full Text] [Related]
22. Ilaprazole-amoxicillin dual therapy at high dose as a first-line treatment for helicobacter pylori infection in Hainan: a single-center, open-label, noninferiority, randomized controlled trial.
Zhang XD; Zhang DY; Chen RX; Chen SJ; Chen C; Zeng F; Huang SM; Li D; Bai FH
BMC Gastroenterol; 2023 Jul; 23(1):249. PubMed ID: 37488516
[TBL] [Abstract][Full Text] [Related]
23. Helicobacter pylori infection.
Malfertheiner P; Camargo MC; El-Omar E; Liou JM; Peek R; Schulz C; Smith SI; Suerbaum S
Nat Rev Dis Primers; 2023 Apr; 9(1):19. PubMed ID: 37081005
[TBL] [Abstract][Full Text] [Related]
24. Management of
Malfertheiner P; Megraud F; Rokkas T; Gisbert JP; Liou JM; Schulz C; Gasbarrini A; Hunt RH; Leja M; O'Morain C; Rugge M; Suerbaum S; Tilg H; Sugano K; El-Omar EM;
Gut; 2022 Aug; ():. PubMed ID: 35944925
[No Abstract] [Full Text] [Related]
25. High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial.
Yu L; Luo L; Long X; Liang X; Ji Y; Graham DY; Lu H
Helicobacter; 2019 Aug; 24(4):e12596. PubMed ID: 31111580
[TBL] [Abstract][Full Text] [Related]
26. Second-line rescue treatment of
Lin TF; Hsu PI
World J Gastroenterol; 2018 Oct; 24(40):4548-4553. PubMed ID: 30386104
[TBL] [Abstract][Full Text] [Related]
27. Susceptibility-guided sequential strategy versus empirical therapy for Helicobacter pylori infection: study protocol for a randomised controlled trial.
Lu K; Lang C; Zou X; Zang L; Sang W; Feng Q; Mu Y; Liu L; Xu C; Zhao J
Trials; 2023 Jun; 24(1):413. PubMed ID: 37337241
[TBL] [Abstract][Full Text] [Related]
28. Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of
Furuta T; Yamade M; Higuchi T; Takahashi S; Ishida N; Tani S; Tamura S; Iwaizumi M; Hamaya Y; Osawa S; Sugimoto K
J Clin Med; 2023 Apr; 12(9):. PubMed ID: 37176551
[TBL] [Abstract][Full Text] [Related]
29. The Efficacy and Safety of 14-day Rabeprazole Plus Amoxicillin High Dose Dual Therapy by Comparing to 14-day Rabeprazole-Containing Hybrid Therapy for the Naïve Helicobacter pylori Infection in Taiwan: A Randomized Controlled Trial.
Tai WC; Yang SC; Yao CC; Wu CK; Liu AC; Lee CH; Kuo YH; Chuah SK; Liang CM
Infect Dis Ther; 2023 May; 12(5):1415-1427. PubMed ID: 37133673
[TBL] [Abstract][Full Text] [Related]
30. Antibiotic resistance in Helicobacter pylori: From potential biomolecular mechanisms to clinical practice.
Lin Y; Shao Y; Yan J; Ye G
J Clin Lab Anal; 2023 Apr; 37(7):e24885. PubMed ID: 37088871
[TBL] [Abstract][Full Text] [Related]
31. High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of
Zhang C; Zhang J; Cheng YJ
Saudi J Gastroenterol; 2023; 29(2):88-94. PubMed ID: 36960527
[TBL] [Abstract][Full Text] [Related]
32. 14-day pantoprazole- and amoxicillin-containing high-dose dual therapy for
Yang Q; He C; Hu Y; Hong J; Zhu Z; Xie Y; Shu X; Lu N; Zhu Y
Front Pharmacol; 2023; 14():1096103. PubMed ID: 36817141
[No Abstract] [Full Text] [Related]
33. PPI-amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: A systematic review and meta-analysis.
Li C; Shi Y; Suo B; Tian X; Zhou L; Song Z
Helicobacter; 2021 Aug; 26(4):e12816. PubMed ID: 34002433
[TBL] [Abstract][Full Text] [Related]
34. A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial.
Song Z; Zhou L; Xue Y; Suo B; Tian X; Niu Z
Helicobacter; 2020 Dec; 25(6):e12762. PubMed ID: 33040439
[TBL] [Abstract][Full Text] [Related]
35. PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis.
Gao CP; Zhang D; Zhang T; Wang JX; Han SX; Graham DY; Lu H
Helicobacter; 2020 Aug; 25(4):e12692. PubMed ID: 32314468
[TBL] [Abstract][Full Text] [Related]
36. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of high-dose dual therapy for Helicobacter pylori rescue therapy: A systematic review and meta-analysis.
Gao CP; Zhou Z; Wang JZ; Han SX; Li LP; Lu H
J Dig Dis; 2016 Dec; 17(12):811-819. PubMed ID: 27977071
[TBL] [Abstract][Full Text] [Related]
38. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.
Fallone CA; Chiba N; van Zanten SV; Fischbach L; Gisbert JP; Hunt RH; Jones NL; Render C; Leontiadis GI; Moayyedi P; Marshall JK
Gastroenterology; 2016 Jul; 151(1):51-69.e14. PubMed ID: 27102658
[TBL] [Abstract][Full Text] [Related]
39. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
[TBL] [Abstract][Full Text] [Related]
40. Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate.
Choi HS; Park DI; Hwang SJ; Park JS; Kim HJ; Cho YK; Sohn CI; Jeon WK; Kim BI
Helicobacter; 2007 Dec; 12(6):638-42. PubMed ID: 18001407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
